Vaneck Pharmaceutical Etf Total Asset
| PPH Etf | USD 88.58 0.64 0.73% |
VanEck Pharmaceutical ETF fundamentals help investors to digest information that contributes to VanEck Pharmaceutical's financial success or failures. It also enables traders to predict the movement of VanEck Etf. The fundamental analysis module provides a way to measure VanEck Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VanEck Pharmaceutical etf.
VanEck |
VanEck Pharmaceutical ETF ETF Total Asset Analysis
VanEck Pharmaceutical's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current VanEck Pharmaceutical Total Asset | 530.46 M |
Most of VanEck Pharmaceutical's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VanEck Pharmaceutical ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, VanEck Pharmaceutical ETF has a Total Asset of 530.46 M. This is much higher than that of the VanEck family and significantly higher than that of the Health category. The total asset for all United States etfs is notably lower than that of the firm.
VanEck Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VanEck Pharmaceutical's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of VanEck Pharmaceutical could also be used in its relative valuation, which is a method of valuing VanEck Pharmaceutical by comparing valuation metrics of similar companies.VanEck Pharmaceutical is currently under evaluation in total asset as compared to similar ETFs.
Fund Asset Allocation for VanEck Pharmaceutical
The fund invests 99.86% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides VanEck Pharmaceutical's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
VanEck Fundamentals
| Price To Earning | 17.83 X | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 1.14 X | |||
| Beta | 0.61 | |||
| Market Capitalization | 877.34 M | |||
| Total Asset | 530.46 M | |||
| One Year Return | 15.50 % | |||
| Three Year Return | 8.00 % | |||
| Five Year Return | 9.50 % | |||
| Ten Year Return | 5.00 % | |||
| Net Asset | 530.46 M | |||
| Last Dividend Paid | 0.35 | |||
| Equity Positions Weight | 99.86 % |
About VanEck Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VanEck Pharmaceutical ETF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VanEck Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VanEck Pharmaceutical ETF based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether VanEck Pharmaceutical ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VanEck Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vaneck Pharmaceutical Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Vaneck Pharmaceutical Etf:Check out VanEck Pharmaceutical Piotroski F Score and VanEck Pharmaceutical Altman Z Score analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
The market value of VanEck Pharmaceutical ETF is measured differently than its book value, which is the value of VanEck that is recorded on the company's balance sheet. Investors also form their own opinion of VanEck Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is VanEck Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VanEck Pharmaceutical's market value can be influenced by many factors that don't directly affect VanEck Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VanEck Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if VanEck Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VanEck Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.